A 22-year-old Harvard dropout who's been at OpenAI for barely two years is about to walk out the door with a $2 billion price tag on his next move.
Meet Miles Wang.
Not a household name.
But maybe not for long.
He's in talks to raise $200 million, with Lightspeed circling to lead the round.
His pitch? AI that finds new uses for old drugs.
Stay with me — this part is the twist.
Building a new drug from scratch takes years and billions.
Most of it burns on safety trials.
But what if the safety work is already done?
That's the bet. Old molecules. New jobs. Faster path to revenue.
Wang co-authored OpenAI research on using AI to accelerate scientific discovery.
Now he's reportedly pulling former OpenAI colleagues along with him.
Same brains. New building.
And he's stepping into a room that's suddenly very crowded.
👉 Chai Discovery — just raised $400M at a $3.8B valuation, this week
👉 Isomorphic Labs (Google DeepMind's spinout) — raised $2.1B in May
👉 Chai's co-founder? Also ex-OpenAI.
Notice the pattern yet?
OpenAI didn't just build ChatGPT.
It built a farm system for the next wave of billion-dollar biotech founders.
Investors aren't chasing chatbots anymore.
They're chasing anyone who can point a language model at a lab bench.
Wang hasn't confirmed the numbers.
The deal isn't signed.
But the money is already circling — and that tells you everything about where Silicon Valley thinks the next trillion dollars is hiding.
That's all for now!
